Health Condition 1: B078- Other viral warts
Conditions
Interventions
Intervention1: Bleomycin: Bleomycin solution with a concentration of 1 mg/ml will be administered intralesionally into the base of the wart depending on the size of the lesion. Warts up to 5 mm will r
Sponsors
Department of Dermatology Venereology and Leprosy
Eligibility
Inclusion criteria
Inclusion criteria: 1. All untreated consecutive patients having single/ multiple lesions of verruca vulgaris. 2. Patients above the age of 14 years.
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating females. 2. Immunocompromised individuals including HIV. 3. Patients known to have hypersensitivity to vitamin D-3. 4. Patients having history of peripheral vascular disorders like scleroderma or Raynaudââ?¬•s phenomenon. 5. Patients with pulmonary fibrosis. 6. History of intake of vitamin D-3, anabolic steroids, bisphosphonates in the last 3 months or history of intravenous chemotherapy with bleomycin in the past. 7. Patients having any significant systemic illness.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare the therapeutic efficacy of intralesional bleomycin and intralesional vitamin D-3 in verruca vulgaris.Timepoint: A total of three sessions at an interval of two weeks shall be instituted in both groups (i.e. 0, 2 and 4 weeks). Patients will be followed at 8th week. | — |
Secondary
| Measure | Time frame |
|---|---|
| NILTimepoint: NIL | — |
Countries
India
Contacts
Public ContactDr Ritu Mittal
Government Medical college and Hospital
Outcome results
None listed